Naslov
Hypogonadotropic hypogonadism in men due to obesity – Is there a place for aromatase inhibitors?

Autori
Belančić, Andrej ; Klobučar Majanović, Sanja

Izvornik
Endocrine oncology and metabolism (1849-8922) 3 (2017), 4; 112-118

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, ostalo

Ključne riječi
Aromatase inhibitors ; Gynecomastia ; Hypogonadism ; Infertility ; Obesity ; Testosterone

Sažetak
High expression of adipose tissue aromatase is a common finding among severely obese men. Aromatase enhances the peripheral conversion of androgens into estrogens, which exerts estradiol-mediated negative feedback on the pituitary and results in inhibition of gonadotropin production and hypotestosteronemia. Therefore, we are scrutinizing aromatase inhibition as a potential novel therapeutic (second- line) strategy for men with hypogonadotropic hypogonadism due to obesity. Several questions remain and will be considered in this review. Could we use aromatase inhibitors to increase gonadotropin secretion and normalize the testosterone/estradiol ratio to improve fertility? Could we use them to treat/ prevent gynecomastia? And finally, if we were to use aromatase inhibitors for these indications, what would be the recommended safe dose that would not trigger the potential detrimental therapy effect on bone mineralization?

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA